These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 28231062)

  • 21. Combined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk.
    Le Marchand L; Hankin JH; Wilkens LR; Pierce LM; Franke A; Kolonel LN; Seifried A; Custer LJ; Chang W; Lum-Jones A; Donlon T
    Cancer Epidemiol Biomarkers Prev; 2001 Dec; 10(12):1259-66. PubMed ID: 11751443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population.
    Chen X; Wang L; Zhi L; Zhou G; Wang H; Zhang X; Hao B; Zhu Y; Cheng Z; He F
    Clin Pharmacol Ther; 2005 Sep; 78(3):249-59. PubMed ID: 16153396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms.
    Gunes A; Dahl ML
    Pharmacogenomics; 2008 May; 9(5):625-37. PubMed ID: 18466106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy.
    Takata K; Saruwatari J; Nakada N; Nakagawa M; Fukuda K; Tanaka F; Takenaka S; Mihara S; Marubayashi T; Nakagawa K
    Eur J Clin Pharmacol; 2006 Jan; 62(1):23-8. PubMed ID: 16385402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype.
    Jiang Z; Dragin N; Jorge-Nebert LF; Martin MV; Guengerich FP; Aklillu E; Ingelman-Sundberg M; Hammons GJ; Lyn-Cook BD; Kadlubar FF; Saldana SN; Sorter M; Vinks AA; Nassr N; von Richter O; Jin L; Nebert DW
    Pharmacogenet Genomics; 2006 May; 16(5):359-67. PubMed ID: 16609368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
    Begas E; Kouvaras E; Tsakalof A; Papakosta S; Asprodini EK
    Biomed Chromatogr; 2007 Feb; 21(2):190-200. PubMed ID: 17221922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic polymorphisms of the CYP3A4, CYP3A5, CYP3A7 and CYP1A2 among the Jordanian population.
    Salameh G; Al Hadidi K; El Khateeb M
    Environ Toxicol Pharmacol; 2012 Jul; 34(1):23-33. PubMed ID: 22426036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.
    Laika B; Leucht S; Heres S; Schneider H; Steimer W
    Pharmacogenomics J; 2010 Feb; 10(1):20-9. PubMed ID: 19636338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans.
    Kimura M; Yamazaki H; Fujieda M; Kiyotani K; Honda G; Saruwatari J; Nakagawa K; Ishizaki T; Kamataki T
    Drug Metab Dispos; 2005 Sep; 33(9):1361-6. PubMed ID: 15980104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphism in cytochrome P450 1A2 and their interaction with risk factors in determining risk of squamous cell lung carcinoma in men.
    Singh AP; Pant MC; Ruwali M; Shah PP; Prasad R; Mathur N; Parmar D
    Cancer Biomark; 2010-2011; 8(6):351-9. PubMed ID: 22072123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The stimulatory role of human cytochrome b5 in the bioactivation activities of human CYP1A2, 2A6 and 2E1: a new cell expression system to study cytochrome P450-mediated biotransformation (a corrigendum report on Duarte et al. (2005) Mutagenesis 20, 93-100).
    Duarte MP; Palma BB; Gilep AA; Laires A; Oliveira JS; Usanov SA; Rueff J; Kranendonk M
    Mutagenesis; 2007 Jan; 22(1):75-81. PubMed ID: 17158518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genotyping of wild-type cytochrome P450 2A6 and whole-gene deletion using human blood samples and a multiplex real-time polymerase chain reaction method with dual-labeled probes.
    Shimizu M; Sawaya R; Kishimoto I; Yamazaki H
    Clin Chim Acta; 2015 Feb; 441():71-4. PubMed ID: 25532948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia.
    Tay JK; Tan CH; Chong SA; Tan EC
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1297-302. PubMed ID: 17611010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liu wei di huang wan, a well-known traditional Chinese medicine, induces CYP1A2 while suppressing CYP2A6 and N-acetyltransferase 2 activities in man.
    Chen Y; Kang Z; Yan J; Yang GP; Tan ZR; Zhou G; Ouyang DS
    J Ethnopharmacol; 2010 Oct; 132(1):213-8. PubMed ID: 20723593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking.
    Dobrinas M; Cornuz J; Pedrido L; Eap CB
    Pharmacogenet Genomics; 2012 Feb; 22(2):143-51. PubMed ID: 22246422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population.
    Soyama A; Saito Y; Hanioka N; Maekawa K; Komamura K; Kamakura S; Kitakaze M; Tomoike H; Ueno K; Goto Y; Kimura H; Katoh M; Sugai K; Saitoh O; Kawai M; Ohnuma T; Ohtsuki T; Suzuki C; Minami N; Kamatani N; Ozawa S; Sawada J
    Drug Metab Pharmacokinet; 2005 Feb; 20(1):24-33. PubMed ID: 15770072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human cytochrome P4501A2.
    Landi MT; Sinha R; Lang NP; Kadlubar FF
    IARC Sci Publ; 1999; (148):173-95. PubMed ID: 10493258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitory effects of cytochrome P450 enzymes CYP1A2, CYP2A6, CYP2E1 and CYP3A4 by extracts and alkaloids of Gelsemium elegans roots.
    Wang Y; Wu S; Chen Z; Zhang H; Zhao W
    J Ethnopharmacol; 2015 May; 166():66-73. PubMed ID: 25764964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic polymorphism analysis of the drug-metabolizing enzyme CYP1A2 in a Uyghur Chinese population: a pilot study.
    Geng T; Zhang XY; Wang L; Wang H; Shi X; Kang L; Hou P; Jin T
    Xenobiotica; 2016; 46(6):542-7. PubMed ID: 26383175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility.
    Dobrinas M; Cornuz J; Oneda B; Kohler Serra M; Puhl M; Eap CB
    Clin Pharmacol Ther; 2011 Jul; 90(1):117-25. PubMed ID: 21593735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.